Pharma Nord (UK) Ltd., Morpeth NE61 2DB, UK.
Department of Physiology, Anatomy and Cell Biology, Andalusian Centre of Developmental Biology, Universidad Pablo de Olavide, 41013 Seville, Spain.
Int J Mol Sci. 2023 Jan 30;24(3):2585. doi: 10.3390/ijms24032585.
The variable success in the outcome of randomised controlled trials supplementing coenzyme Q10 (CoQ10) may in turn be associated with a number of currently unresolved issues relating to CoQ10 metabolism. In this article, we have reviewed what is currently known about these factors and where gaps in knowledge exist that need to be further elucidated. Issues addressed include (i) whether the bioavailability of CoQ10 could be improved; (ii) whether CoQ10 could be administered intravenously; (iii) whether CoQ10 could be administered via alternative routes; (iv) whether CoQ10 can cross the blood-brain barrier; (v) how CoQ10 is transported into and within target cells; (vi) why some clinical trials supplementing CoQ10 may have been unsuccessful; and (vii) which is the most appropriate tissue for the clinical assessment of CoQ10 status.
随机对照试验中补充辅酶 Q10(CoQ10)的结果存在差异,这可能与 CoQ10 代谢相关的一些尚未解决的问题有关。在本文中,我们回顾了目前已知的这些因素,以及需要进一步阐明的知识空白。讨论的问题包括:(i)CoQ10 的生物利用度是否可以提高;(ii)CoQ10 是否可以静脉给药;(iii)CoQ10 是否可以通过其他途径给药;(iv)CoQ10 是否可以穿过血脑屏障;(v)CoQ10 如何被转运到靶细胞内;(vi)为什么一些补充 CoQ10 的临床试验可能不成功;以及(vii)评估 CoQ10 状态的最合适的组织是哪一个。